Protagenic Therapeutics (Protagenic Therapeutics) Debt-to-Equity : 0.00 (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Protagenic Therapeutics Debt-to-Equity?

Protagenic Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Protagenic Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Protagenic Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $3.67 Mil. Protagenic Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Protagenic Therapeutics's Debt-to-Equity or its related term are showing as below:

PTIX' s Debt-to-Equity Range Over the Past 10 Years
Min: -8.33 Med: -0.74 Max: 0.05
Current: 0.12

During the past 13 years, the highest Debt-to-Equity Ratio of Protagenic Therapeutics was 0.05. The lowest was -8.33. And the median was -0.74.

PTIX's Debt-to-Equity is ranked better than
55.04% of 1072 companies
in the Biotechnology industry
Industry Median: 0.15 vs PTIX: 0.12

Protagenic Therapeutics Debt-to-Equity Historical Data

The historical data trend for Protagenic Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protagenic Therapeutics Debt-to-Equity Chart

Protagenic Therapeutics Annual Data

Trend

Jun14

Jun15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-0.44

-1.20

0.03

0.05

Protagenic Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.05	0.06	0.07	0.10	-

Competitive Comparison of Protagenic Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Protagenic Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protagenic Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protagenic Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Protagenic Therapeutics's Debt-to-Equity falls into.

Protagenic Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Protagenic Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.668
	=	0.00

Protagenic Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	0)	/	3.668
	=	0.00

Protagenic Therapeutics (NAS:PTIX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Protagenic Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Protagenic Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Protagenic Therapeutics (Protagenic Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protagenic Therapeutics Inc (NAS:PTIX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

MBP:Germany

Address

149 Fifth Avenue, Suite 500, New York, NY, USA, 10010

Website

https://www.protagenic.com

Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Executives

Alexander K. Arrow	officer: Chief Financial Officer	PO BOX 3094, REDWOOD CITY CA 94064
Jennifer Buell	director	3 FORBES ROAD, LEXINGTON MA 02421
Brian Corvese	director	C/O ANTIGENICS INC., 162 FIFTH AVENUE, SUITE 900, NEW YORK NY 10010
Robert Benjamin Stein	director	C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Khalil Barrage	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Gregory Ekizian	director	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Robert Ziroyan	officer: COO / Interim President	149 FIFTH AVENUE, SUITE 500, NEW YORK NY 10010
Joshua Silverman	director	IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Garo H Armen	director, 10 percent owner, officer: See Remarks	3 FORBES ROAD, LEXINGTON MA 02421
Edward J Gildea	director, officer: Chief Executive Officer	C/O CONVERTED ORGANICS INC., 7A COMMERCIAL WHARF WEST, BOSTON MA 02110
David J Horin	officer: Chief Financial Officer	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Jonathan Schechter	director	C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Nathan Yu-gai Fong	officer: Chief Financial Officer	THE ORCHARD ENTERPRISES, INC., 23 E. 4TH ST., 3RD FL., NEW YORK NY 10003
Sharon Siegel	officer: Chief Marketing Officer	C/O ATRINSIC, INC., 469 SEVENTH AVENUE, 10TH FLOOR, NEW YORK NY 10018
Raymond Musci	director, officer: Exec VP, Corporate Development	C/O BRILLIANT DIGITAL ENTERTAINMENT INC, 6355 TOPANGA CANYON BOULEVARD SUITE 520, WOODLAND HILLS CA 91367